Global Antisense Oligonucleotide Therapy for the Nervous System Market Growth (Status and Outlook) 2024-2030

Global Antisense Oligonucleotide Therapy for the Nervous System Market Growth (Status and Outlook) 2024-2030

Antisense Oligonucleotides (ASOs) are a class of nucleic acid drugs designed to target specific RNA molecules within cells. They work by binding to complementary RNA sequences, which can modulate gene expression in various ways. ASOs have been developed to treat a wide range of genetic and other diseases

The global Antisense Oligonucleotide Therapy for the Nervous System market size is projected to grow from US$ 3938 million in 2024 to US$ 10620 million in 2030; it is expected to grow at a CAGR of 18.0% from 2024 to 2030.

LPI (LP Information)' newest research report, the “Antisense Oligonucleotide Therapy for the Nervous System Industry Forecast” looks at past sales and reviews total world Antisense Oligonucleotide Therapy for the Nervous System sales in 2022, providing a comprehensive analysis by region and market sector of projected Antisense Oligonucleotide Therapy for the Nervous System sales for 2023 through 2029. With Antisense Oligonucleotide Therapy for the Nervous System sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Antisense Oligonucleotide Therapy for the Nervous System industry.

This Insight Report provides a comprehensive analysis of the global Antisense Oligonucleotide Therapy for the Nervous System landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Antisense Oligonucleotide Therapy for the Nervous System portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Antisense Oligonucleotide Therapy for the Nervous System market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Antisense Oligonucleotide Therapy for the Nervous System and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Antisense Oligonucleotide Therapy for the Nervous System.

United States market for Antisense Oligonucleotide Therapy for the Nervous System is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for Antisense Oligonucleotide Therapy for the Nervous System is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for Antisense Oligonucleotide Therapy for the Nervous System is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key Antisense Oligonucleotide Therapy for the Nervous System players cover Ionis Pharmaceuticals, Biogen, Sobi, Nippon Shinyaku, Jazz Pharmaceuticals, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.

This report presents a comprehensive overview, market shares, and growth opportunities of Antisense Oligonucleotide Therapy for the Nervous System market by product type, application, key players and key regions and countries.

Segmentation by Type:
Intrathecal Injection
Intravenous Injections
Other

Segmentation by Application:
Neuromuscular Diseases
hATTR
Other

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

Segmentation by Type:
Intrathecal Injection
Intravenous Injections
Other

Segmentation by Application:
Neuromuscular Diseases
hATTR
Other

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Ionis Pharmaceuticals
Biogen
Sobi
Nippon Shinyaku
Jazz Pharmaceuticals

Please note: The report will take approximately 2 business days to prepare and deliver.